Bibn-4096;bibn 4096BS

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Bibn-4096;bibn 4096BS
• 英文别名: N-[1-[[6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
• 化学式: C₃₈H₄₇Br₂N₉O₅
• 分子量: 869.6
• InChiKey: ITIXDWVDFFXNEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  54
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  177
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] NEW THERAPEUTIC APPROACH TO LUNG DISEASE<br/>[FR] NOUVELLE APPROCHE THÉRAPEUTIQUE VIS-À-VIS D'UNE MALADIE PULMONAIRE
  申请人：UNIV CALIFORNIA

  公开号：WO2020252368A2

  公开（公告）日：2020-12-17

  The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such as the CGRP signaling. Also disclosed is the pharmaceutical composition for preventing and/or treating a pulmonary edema and/or other pulmonary disease, particularly, NEHI, comprising one or more CGRP signaling antagonist and/or inhibitor of the present disclosure.